Home / Astrazeneca PLC (AZN)
Astrazeneca PLC
Forward trial catalysts linked to AZN
CSA tracks 17 forward catalysts for Astrazeneca PLC across 11 assets, spanning Phase 3. The nearest is a readout expected Dec 23, 2026 (day precision). Confidence across its tracked catalysts breaks down as 17 medium. Tracked indications include Systemic Lupus Erythematosus, Lupus Nephritis, Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus, and 32 more.
AZN in the full snapshot
The free sample on this page is a slice. In the current full CSA snapshot, Astrazeneca PLC has:
Forward catalysts by year
2026 · 42027 · 282028 · 352029 · 362030 · 132031 · 62032 · 12033 · 3
Every catalyst in the snapshot comes with its date, date confidence and source link.
57 trials behind these assets
| Asset | Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|---|
| benralizumab | NCT04157348 | Phase 3 | Active, not recruiting | 2023-08-10 | Experimental | AstraZeneca | Eosinophilic Granulomatous Vasculitis |
| datopotamab deruxtecan | NCT04656652 | Phase 3 | Active, not recruiting | 2024-05-10 | Experimental | Daiichi Sankyo | Non-small Cell Lung Cancer |
| datopotamab deruxtecan | NCT05104866 | Phase 3 | Active, not recruiting | 2024-07-24 | Experimental | AstraZeneca | Breast Cancer |
| tezepelumab | NCT06740045 | Phase 3 | Not yet recruiting | 2025-03 | Experimental | Dr. Andrew Thamboo, MD | Asthma; Chronic Rhinosinusitis With Nasal Polyps |
| camizestrant | NCT04964934 | Phase 3 | Active, not recruiting | 2025-06-30 | Experimental | AstraZeneca | ER-Positive HER2-Negative Breast Cancer |
| laroprovstat | NCT06834932 | Phase 2/3 | Active, not recruiting | 2025-07-03 | Experimental | AstraZeneca | Dyslipidaemia |
| anifrolumab | NCT04877691 | Phase 3 | Active, not recruiting | 2025-08-22 | Experimental | AstraZeneca | Systemic Lupus Erythematosus |
| datopotamab deruxtecan | NCT05374512 | Phase 3 | Active, not recruiting | 2025-08-25 | Experimental | AstraZeneca | Breast Cancer |
| camizestrant | NCT04711252 | Phase 3 | Active, not recruiting | 2026-06-26 | Experimental | AstraZeneca | ER-Positive HER2-Negative Breast Cancer |
| datopotamab deruxtecan | NCT06564844 | Phase 3 | Active, not recruiting | 2026-07-10 | Experimental | AstraZeneca | Non-small Cell Lung Cancer |
| ravulizumab | NCT05644561 | Phase 3 | Active, not recruiting | 2026-07-15 | Experimental | Alexion Pharmaceuticals, Inc. | Generalized Myasthenia Gravis; gMG |
| datopotamab deruxtecan | NCT06417814 | Phase 3 | Recruiting | 2026-09-30 | Experimental | AstraZeneca | Metastatic Non-small Cell Lung Cancer |
| benralizumab | NCT05692180 catalyst | Phase 3 | Active, not recruiting | 2026-12-23 | Experimental | AstraZeneca | Asthma |
| laroprovstat | NCT07000136 catalyst | Phase 3 | Active, not recruiting | 2027-01-04 | Experimental | AstraZeneca | Heterozygous Familial Hypercholesterolaemia |
| laroprovstat | NCT07000123 catalyst | Phase 3 | Active, not recruiting | 2027-01-11 | Experimental | AstraZeneca | Cardiovascular Disease |
| anifrolumab | NCT05138133 catalyst | Phase 3 | Active, not recruiting | 2027-02-23 | Experimental | AstraZeneca | Lupus Nephritis |
| camizestrant | NCT05774951 catalyst | Phase 3 | Recruiting | 2027-04-20 | Experimental | AstraZeneca | Breast Cancer, Early Breast Cancer |
| datopotamab deruxtecan | NCT06103864 catalyst | Phase 3 | Recruiting | 2027-07-28 | Experimental | AstraZeneca | Breast Cancer |
| laroprovstat | NCT07619131 | Phase 3 | Recruiting | 2027-07-30 | Active comparator | AstraZeneca | Hypercholesterolaemia |
| ravulizumab | NCT07596784 catalyst | Phase 3 | Recruiting | 2027-08-17 | Experimental | Alexion Pharmaceuticals, Inc. | Generalized Myasthenia Gravis; gMG |
| datopotamab deruxtecan | NCT05629585 catalyst | Phase 3 | Active, not recruiting | 2027-09-20 | Experimental | AstraZeneca | Breast Cancer |
| saruparib | NCT06120491 catalyst | Phase 3 | Active, not recruiting | 2027-09-30 | Experimental | AstraZeneca | Metastatic Castration-Sensitive Prostate Cancer |
| puxitatug samrotecan | NCT07044336 catalyst | Phase 3 | Recruiting | 2027-10-15 | Experimental | AstraZeneca | Endometrial Cancer; Malignant Solid Tumour |
| datopotamab deruxtecan | NCT05687266 catalyst | Phase 3 | Active, not recruiting | 2027-11-01 | Experimental | AstraZeneca | NSCLC |
| volrustomig | NCT06079671 catalyst | Phase 3 | Recruiting | 2027-11-26 | Experimental | AstraZeneca | Locally Advanced Cervical Cancer |
| datopotamab deruxtecan | NCT07205822 catalyst | Phase 3 | Recruiting | 2028-02-02 | Experimental | AstraZeneca | Breast Cancer |
| tezepelumab | NCT07363642 catalyst | Phase 3 | Recruiting | 2028-02-07 | Experimental | AstraZeneca | Severe Asthma |
| benralizumab | NCT06512883 catalyst | Phase 3 | Recruiting | 2028-02-20 | Experimental | AstraZeneca | Eosinophilic Granulomatosis With Polyangiitis (EGPA); Hypereosinophilia Syndrome (HES) |
| baxdrostat dapagliflozin | NCT06268873 catalyst | Phase 3 | Active, not recruiting | 2028-02-24 | Experimental | AstraZeneca | Chronic Kidney Disease and Hypertension |
| datopotamab deruxtecan | NCT06350097 catalyst | Phase 3 | Recruiting | 2028-03-21 | Experimental | AstraZeneca | Non-small Cell Lung Cancer |
| tezepelumab | NCT06023589 | Phase 3 | Recruiting | 2028-05-31 | Experimental | AstraZeneca | Asthma |
| anifrolumab | NCT07751848 | Phase 3 | Recruiting | 2028-08-25 | Experimental | AstraZeneca | Lupus Erythematosus, Systemic |
| anifrolumab | NCT05835310 | Phase 3 | Recruiting | 2028-10-05 | Experimental | AstraZeneca | Systemic Lupus Erythematosus |
| volrustomig | NCT06097728 | Phase 3 | Active, not recruiting | 2028-11-16 | Experimental | AstraZeneca | Unresectable Pleural Mesothelioma |
| datopotamab deruxtecan | NCT06112379 | Phase 3 | Active, not recruiting | 2028-11-20 | Experimental | AstraZeneca | Breast Cancer |
| ravulizumab | NCT07024563 | Phase 3 | Recruiting | 2028-11-29 | Experimental | Alexion Pharmaceuticals, Inc. | IgAN; IgAVN; Immunoglobulin A Nephropathy; Immunoglobulin A Vasculitis Associated Nephriti… |
| tezepelumab | NCT07302516 | Phase 3 | Not yet recruiting | 2028-12 | Experimental | Qilu Pharmaceutical Co., Ltd. | Asthma |
| anifrolumab | NCT07430306 | Phase 3 | Recruiting | 2029-01-26 | Other | AstraZeneca | Systemic Lupus Erythematosus |
| datopotamab deruxtecan | NCT07291037 | Phase 3 | Recruiting | 2029-01-29 | Experimental | AstraZeneca | Non-small Cell Lung Cancer (NSCLC) |
| volrustomig | NCT05984277 | Phase 3 | Active, not recruiting | 2029-02-28 | Experimental | AstraZeneca | Metastatic Non-small Cell Lung Cancer |
| camizestrant | NCT07647328 | Phase 3 | Recruiting | 2029-02-28 | Experimental | AstraZeneca | ER-Positive HER2-Negative Breast Cancer |
| datopotamab deruxtecan | NCT05555732 | Phase 3 | Active, not recruiting | 2029-05-11 | Experimental | Daiichi Sankyo | Metastatic Non Small Cell Lung Cancer |
| datopotamab deruxtecan | NCT07129993 | Phase 2/3 | Recruiting | 2029-06-01 | Experimental | Daiichi Sankyo | Urothelial Cancer; Bladder Cancer |
| tezepelumab | NCT07013123 | Phase 3 | Not yet recruiting | 2029-08-18 | Experimental | University Hospital, Montpellier | Severe Asthma; Allergy to House Dust Mites |
| laroprovstat | NCT07000357 | Phase 3 | Recruiting | 2029-10-26 | Experimental | AstraZeneca | Cardiovascular Disease |
| baxdrostat dapagliflozin | NCT06677060 | Phase 3 | Recruiting | 2029-12-17 | Experimental | AstraZeneca | Heart Failure |
| camizestrant | NCT06380751 | Phase 3 | Recruiting | 2029-12-18 | Experimental | AstraZeneca | Advanced Breast Cancer |
| saruparib | NCT06380751 | Phase 3 | Recruiting | 2029-12-18 | Experimental | AstraZeneca | Advanced Breast Cancer |
| baxdrostat dapagliflozin | NCT06742723 | Phase 3 | Recruiting | 2029-12-18 | Experimental | AstraZeneca | Chronic Kidney Disease and Hypertension |
| benralizumab | NCT07444567 | Phase 3 | Recruiting | 2029-12-27 | Experimental | AstraZeneca | Asthma; Eosinophilic Granulomatosis With Polyangiitis (EGPA); Hypereosinophilic Syndrome (… |
| datopotamab deruxtecan | NCT06357533 | Phase 3 | Recruiting | 2029-12-28 | Experimental | AstraZeneca | Non-Small Cell Lung Cancer |
| datopotamab deruxtecan | NCT05215340 | Phase 3 | Active, not recruiting | 2030-03-04 | Experimental | Daiichi Sankyo | Metastatic Non Small Cell Lung Cancer |
| camizestrant | NCT05952557 | Phase 3 | Active, not recruiting | 2030-03-04 | Experimental | AstraZeneca | Breast Cancer, Early Breast Cancer |
| volrustomig | NCT06129864 | Phase 3 | Recruiting | 2030-04-17 | Experimental | AstraZeneca | Locally Advanced Head and Neck Squamous Cell Carcinoma |
| datopotamab deruxtecan | NCT07720284 | Phase 3 | Recruiting | 2030-09-11 | Experimental | AstraZeneca | High-risk Muscle Invasive Urothelial Carcinoma |
| saruparib | NCT07711002 | Phase 3 | Not yet recruiting | 2031-06-17 | Experimental | AstraZeneca | Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) |
| anifrolumab | NCT07691970 | Phase 3 | Recruiting | 2032-12-30 | Experimental | AstraZeneca | Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus |
| saruparib | NCT06952803 | Phase 3 | Recruiting | 2033-03-31 | Experimental | AstraZeneca | Prostate Cancer |
Every trial the CSA sample links to AZN's tracked assets, including trials another sponsor runs and trials where the asset is not the experimental arm.
Conditions studied
Eosinophilic Granulomatous VasculitisAsthmaEosinophilic Granulomatosis With Polyangiitis (EGPA)Hypereosinophilia Syndrome (HES)Hypereosinophilic Syndrome (HES)DyslipidaemiaCardiovascular DiseaseHeterozygous Familial HypercholesterolaemiaHypercholesterolaemiaSystemic Lupus ErythematosusLupus NephritisSystemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus ErythematosusLupus Erythematosus, SystemicER-Positive HER2-Negative Breast CancerBreast Cancer, Early Breast CancerAdvanced Breast CancerNon-small Cell Lung CancerBreast CancerMetastatic Non Small Cell Lung CancerNSCLCMetastatic Non-small Cell Lung CancerUrothelial CancerBladder CancerNon-small Cell Lung Cancer (NSCLC)High-risk Muscle Invasive Urothelial CarcinomaGeneralized Myasthenia GravisgMGIgANIgAVNImmunoglobulin A NephropathyImmunoglobulin A Vasculitis Associated NephritisHenoch-schonlein Purpura NephritisIgA VasculitisMetastatic Castration-Sensitive Prostate CancerProstate CancerMetastatic Hormone-Sensitive Prostate Cancer (mHSPC)Endometrial CancerMalignant Solid TumourLocally Advanced Cervical CancerUnresectable Pleural Mesothelioma
and 6 more.
!
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This sponsor's catalysts are a slice of the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 →